Abingdon, UK, 10th June 2021. OBS Medical Limited (OBS) is pleased to announce its partnership with Therapeutic Monitoring Systems Inc (TMS), an Ottawa based company specialising in complexity science, variability analysis and artificial intelligence. The partnership will offer healthcare organisations a suite of predictive analytics for advanced clinical decision support that are vendor and device agnostic.
As part of the partnership, OBS Medical will assist TMS to commercially develop three novel variability-derived clinical decision support software products and to gain necessary regulatory approvals. The first Clinical Decision Support System (CDSS) in this suite of predictive analytics will be Extubation Advisor (EA).
Extubation Advisor (EA) is a bedside decision support tool developed to determine a patient’s readiness for liberation from a ventilator life support machine, a critical transition for a critically ill patient in the intensive care unit. EA provides proprietary estimation of the risk of extubation failure based on a score derived from the patient’s own respiratory rate variability and provides a standardized assessment of a patient’s readiness for extubation.
Simon Didcote, CEO, OBS said: “With an initial launch of Extubation Advisor (EA) in Europe this month, we are pleased to be part of a team helping drive the adoption of predictive analytics that are relevant in helping today’s challenges within the ICU, as well as a suite of complementary AI driven technologies designed for the hospital of the future in the pipeline.”
Dr Andrew Seely, CEO, TMS said: “We are delighted to be working with OBS Medical with their long-standing experience and expertise in predictive analytics requiring regulatory approval; our two companies bring exciting complementary technologies that will help transform monitoring and improve care.”
The partnerships combined suite of predictive analytics will span the continuum of care and will markedly improve quality and efficiency of patient care, by enhancing the way clinicians make decisions in the ICU and Emergency Rooms and Medical / Surgical Units.
About Therapeutic Monitoring Systems Inc (TMS)
TMS vision is to transform routine bedside monitoring into valuable actionable information to improve patient care. TMS mission is to research, develop and commercialize innovative point-of-care clinical decision support to improve the quality and efficiency of acute care medicine, combining proprietary variability analysis and artificial intelligence. www.therapeuticmonitoring.com
TMS was founded by Dr. Andrew J.E. Seely, who is a practicing critical care intensivist and a thoracic surgeon at the Ottawa Hospital, Full Professor at the University of Ottawa, and Director of the Dynamic Analysis Laboratory (DAL) in the Ottawa Hospital Research Institute (OHRI).
Media Contacts: Wendy Threader | wthreader@therapeuticmonitoring.com
About Extubation Advisor (EA)
Extubation Advisor (EA) is the first clinical decision support tool developed to provide prediction of extubation outcomes and standardize the assessment of extubation readiness. EA combines a respiratory rate variability (RRV) derived predictive model of the risk of extubation failure called the WAVE score, the rapid shallow breathing index (RSBI), clinical impression of extubation failure risk, and a standardized extubation readiness checklist to generate an extubation report for clinical decision-making.
Find Out More about Extubation Advisor here: Extubation Advisor (EA)